Tumor Necrosis Factor-mediated survival of CD169+ cells promotes immune activation during vesicular stomatitis virus infection

Shinde, Prashant V.; Xu, Haifeng C.; Maney, Sathish Kumar; Kloetgen, Andreas; Namineni, Sukumar; Zhuang, Yuan

Published in:
Journal of Virology

DOI:
10.1128/JVI.01637-17

Publication date:
2018

Document Version
Publisher's PDF, also known as Version of record

Link to publication in Discovery Research Portal

Citation for published version (APA):

General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Download date: 26. Oct. 2019
Tumor Necrosis Factor-Mediated Survival of CD169⁺ Cells Promotes Immune Activation during Vesicular Stomatitis Virus Infection

Prashant V. Shinde, a,b Haifeng C. Xu, a,b Sathish Kumar Maney, a,b Andreas Kloetgen, c,d Sukumar Namineni, e,n Yuan Zhuang, a,b Nadine Honke, f Namir Shaabani, g Nicolas Bellora, h Mareike Doerrenberg, i, Mirko Trilling, j Vitaly I. Pozdeev, a,b Nico van Rooijen, k Stefanie Scheu, k Klaus Pfeffer, k Paul R. Crocker, m Masato Tanaka, m Sujitha Duggimpudi, n Percy Knolle, n Mathias Heikkenwalder, o, Tjuergen Ruland, o, Natalia V. Mak, a, Dirk Brenner, r, Aleksandra A. Pandyra, s Jessica I. Hoell, s Arndt Borkhardt, t Dieter Häussinger, t Karl S. Lang, t Philipp A. Lang, t

a Department of Molecular Medicine II, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany
b Department of Gastroenterology, Hepatology, and Infectious Diseases, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany
c Department of Pediatric Oncology, Hematology and Clinical Immunology, Center for Child and Adolescent Health, Heinrich Heine University, Medical Faculty, Düsseldorf, Germany
d Computational Biology of Infection Research, Helmholtz Center for Infection Research, Braunschweig, Germany
e Institute of Virology, TU Munich, Munich, Germany
f Institute of Immunology, Medical Faculty, University of Duisburg-Essen, Essen, Germany
g Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, USA
h Instituto Andino Patagónico de Tecnologías Biológicas y Geoenambientes (IPATEC), Universidad Nacional del Comahue-CONICET, Bariloche, Argentina
i Institute for Virology of the University Hospital Essen, University of Duisburg-Essen, Essen, Germany
j Department of Cell Biology, Vrije University Medical Center, Amsterdam, Netherlands
k Institute of Medical Microbiology and Hospital Hygiene, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany
l Division of Cell Signalling and Immunology, School of Life Sciences, University of Dundee, Dundee, United Kingdom
m Laboratory of Immune Regulation, School of Life Science, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
n Department of Molecular Immunology, Technische Universität Munich and Helmholtz Zentrum Munich, Munich, Germany
o Division of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany
p Institut für Klinische Chemie und Pathobiochemie, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
q Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada
r Department of Infection and Immunity, Experimental and Molecular Immunology, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg
s Odense Research Center for Anaphylaxis (ORCA), Department of Dermatology and Allergy Center, Odense University Hospital, University of Southern Denmark, Odense, Denmark
t Department of Rheumatology, Hiller Research Center Rheumatology, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany
u German Cancer Consortium (DKTK), partner site Munich, Germany
v German Center for Infection Research (DZIF), partner site Munich, Germany
w Center for Translational Cancer Research (TranslaTUM), Technical University of Munich, Munich, Germany

ABSTRACT Innate immune activation is essential to mount an effective antiviral response and to prime adaptive immunity. Although a crucial role of CD169⁺ cells during vesicular stomatitis virus (VSV) infections is increasingly recognized,
factors regulating CD169+ cells during viral infections remain unclear. Here, we show that tumor necrosis factor is produced by CD11b+ Ly6C+ Ly6G+ cells following infection with VSV. The absence of TNF or TNF receptor 1 (TNFR1) resulted in reduced numbers of CD169+ cells and in reduced type I interferon (IFN-I) production during VSV infection, with a severe disease outcome. Specifically, TNF triggered RelA translocation into the nuclei of CD169+ cells; this translocation was inhibited when the paracaspase MALT-1 was absent. Consequently, MALT1 deficiency resulted in reduced VSV replication, defective innate immune activation, and development of severe disease. These findings indicate that TNF mediates the maintenance of CD169+ cells and innate and adaptive immune activation during VSV infection.

**IMPORTANCE** Over the last decade, strategically placed CD169+ metallophilic macrophages in the marginal zone of the murine spleen and lymph nodes (LN) have been shown to play a very important role in host defense against viral pathogens. CD169+ macrophages have been shown to activate innate and adaptive immunity via "enforced virus replication," a controlled amplification of virus particles. However, the factors regulating the CD169+ macrophages remain to be studied. In this paper, we show that after vesicular stomatitis virus infection, phagocytes produce tumor necrosis factor (TNF), which signals via TNFR1, and promote enforced virus replication in CD169+ macrophages. Consequently, lack of TNF or TNFR1 resulted in defective immune activation and VSV clearance.

**KEYWORDS** TNF, MALT1, innate immunity, interferon, NF-κB, innate immunity, interferons, tumor necrosis factor
doses of VSV, replication of VSV in CD169⁺ cells in the spleen and lymph node tissue is important for inducing protective immunity and preventing CNS infection (9, 10). The VSV backbone is also used during vaccination to induce protective immunity against viruses such as Ebola virus (25).

The role of tumor necrosis factor (TNF) in marginal-zone development and marginal-zone function is controversial. Although reports show that marginal-zone development is impaired and fewer marginal-zone macrophages are present in TNF-deficient and p55-TNFR (tumor necrosis factor receptor 1 [TNFR1])-deficient mice (26), other reports suggest that TNF triggers marginal-zone macrophage depletion after infection (27, 28). It has also been shown that TNFR1-deficient mice are less susceptible to West Nile virus infection as a result of an uncompromised blood-brain barrier (29). However, other studies utilizing herpes simplex virus 1 as an infection model showed that TNFR1-deficient mice are more susceptible to virus infection (30, 31). It is clear that TNF-deficient mice exhibit CD169⁺ cells in the spleen, whereas this cell population is absent in Lta⁻/⁻ mice (26, 27). Furthermore, the proliferation of antiviral T cells can be induced in TNF-deficient animals (28, 32). These findings suggest that TNF, which is crucial for overcoming bacterial infections (33–36), plays a minor role in antiviral immunity.

In this study, we found that absence of TNF reduced the number of CD169⁺ cells; inhibited IFN-I production; and, consequently, led to a severe disease outcome during infection with VSV. These effects were mainly transmitted by TNFR1 and were dependent on canonical nuclear factor κB (NF-κB).

RESULTS

**TNF production by CD11b⁺ Ly6C⁺ Ly6G⁺ cells following VSV infection.** TNF can be detected during an infection with VSV (32, 37). Consistently, we found that TNF expression levels were higher in the spleen after infection with VSV than in uninfected controls (Fig. 1A). Backgating of intracellular-TNF-producing cells showed that TNF-producing cells are a heterogeneous CD11b⁺ CD19⁻ population (Fig. 1B and C). Therefore, we hypothesized that TNF was likely not expressed by B or T cells during infection. Accordingly, we observed TNF mRNA expression levels in Cdb⁻/⁻, B-cell-deficient Jh⁻/⁻, and Rag1⁻/⁻ mice that were comparable to those in wild-type (WT) mice (Fig. 1D). TNF-producing cells could be predominantly characterized as CD11b⁺ CD11c⁻ Ly6c⁺ Ly6G⁺ major histocompatibility complex class II negative (MHC-II⁻) (Fig. 1E). Consistent with reports that neutrophils (38, 39) and CD11b⁺ Ly6C⁺ Ly6G⁺ cells (40) are important during early defense against bacterial and viral infections via production of proinflammatory cytokines, such as interleukin 1b (IL-1b), IL-6, TNF, and IFN-I, we found a significant increase of TNF⁺ CD11b⁺ Ly6C⁺ Ly6G⁺ cells (Fig. 1F). Treatment with clodronate encapsulated in liposomes (clodronate liposomes) can deplete phagocytic cells in mice (Fig. 1G) (41, 42). Accordingly, clodronate depletion reduced TNF expression after VSV infection, suggesting a role of these phagocytic cells in the production of TNF (Fig. 1H). However, when we employed diphtheria toxin receptor (DTR)-induced specific depletion of CD169⁺ cells and CD11c⁺ cells, we did not observe a reduction in TNF production (Fig. 1H). Taken together, these findings indicate that TNF production following intravenous VSV infection is triggered by CD11b⁺ CD11c⁻ Ly6c⁺ Ly6G⁺ phagocytes.

**TNF triggers the maintenance of CD169⁺ cells during viral infection to protect animals against the development of severe disease.** To determine whether TNF affects the outcome after VSV infection, we infected WT and TNF-deficient mice. TNF-deficient mice developed severe VSV infection in comparison to WT mice (Fig. 2A). A neutralizing antibody titer was achieved later in TNF-deficient mice than in WT mice after infection with low doses of VSV (Fig. 2B). Since IFN-I is critical to overcome an infection with VSV (15), we measured IFN-α and IFN-β in the sera of infected animals. IFN-α production was impaired in TNF-deficient mice compared to control animals (Fig. 2C). However, IFN-β was undetectable in the sera of animals infected with 10⁵ PFU VSV (Fig. 2C). Previous findings showed that CD169⁺ cells contribute to innate immune
FIG 1 Vesicular stomatitis virus infection leads to infiltration of TNF-producing phagocytes. (A to F) WT mice were infected with 2 × 10^6 PFU VSV. (A) TNF-α mRNA expression levels in WT spleen tissue were determined at the indicated time points after infection (n = 4 to 10). (B) Surface molecule expression of CD11b, CD11c, CD8, and CD19 on TNF^+ cells 4 h after infection (purple gate, whole spleen; pink gate, TNF^+ cells; one representative result out of 5 is shown). Numbers below the histograms indicate fluorescence intensities. FSC, forward scatter; SSC, side scatter. (C) Splenocytes from WT mice were stained for intracellular-TNF production. TNF^+ cells were determined as percentages of total CD11b^+ cells (n = 5). (D) TNF-α mRNA expression in the spleens of WT, Jh^−/−, Rag^−/−, and CD8^−/− mice was determined 4 h after infection (n = 5 or 6). (E) Surface molecule expression of TNF-producing cells 4 h after infection. CD3^−CD8^−CD19^−NK1.1^ cells were further characterized for (Continued on next page)
TNF Promotes CD169+ Macrophage Survival

Journal of Virology

Production found infectious VSV in tissue from TNFR1-deficient mice (Fig. 3G). Consequently, VSV, the number of CD169+ contributed to IFN-I production following VSV infection. Shortly after infection with ISGs, viral injection mice (Fig. 2L). However, the decrease of CD169+ in Tnfrsf1b mice (Fig. 2M). These findings indicate that TNF is necessary to sustain virus replication in spleen tissue of WT and Tnfa−/− mice. The expression of VSV glycoprotein (VSV-G) was detected in smaller quantities in spleen tissue harvested from TNF-deficient animals than in spleen tissue harvested from WT mice after VSV infection (Fig. 2I and J). Consistently, early VSV titers after infection were lower in Tnfa−/− mice than in control mice, a condition that negatively affected antiviral immune activation (Fig. 2K).

Injection of UV light (UV)-inactivated virus could increase TNF mRNA expression in WT mice (Fig. 2L). However, the decrease of CD169+ cells was dependent on live virus, because UV-inactivated virus did not affect CD169+ cells in spleen tissue of Tnfa−/− mice (Fig. 2M). These findings indicate that TNF is necessary to sustain virus replication in the early hours of infection but is dispensable for sterile innate immune activation. Notably, CD169−/− mice exhibited VSV-G expression in spleen tissue, a finding indicating that downregulation of the protein CD169 would not cause absence of virus replication (Fig. 2N). Taken together, these findings indicate that the absence of TNF results in defective antiviral innate immune activation after infection with VSV.

CD169+ cell maintenance via TNFR1 results in productive VSV replication and immune activation. To further characterize the role of TNF during viral infection, we infected TNFR1- and TNFR2-deficient mice with VSV. In line with findings from TNF-deficient animals, the absence of TNFR1, but not that of TNFR2, resulted in a decrease in the number of CD169+ cells in spleen tissue (Fig. 3A and B). Furthermore, VSV-G production was lower in Tnfrsf1a−/− animals than in WT or Tnfrsf1b−/− mice (Fig. 3A). Consistently, VSV titers were reduced in spleen tissue shortly after infection in Tnfrsf1a−/− animals, in sharp contrast to the findings in WT and Tnfrsf1b−/− mice (Fig. 3C). Interestingly, IFN-I production was defective in Tnfrsf1a−/− mice but was also lower in Tnfrsf1b−/− animals than in WT control mice (Fig. 3D). IFN-I is necessary for the expression of antivirally active ISGs (1). Consistently, we found reduced expression of ISGs in the CNS of Tnfrsf1a−/− mice after infection with VSV (Fig. 3E). Defective ISG expression was not found to the same extent in Tnfrsf1b−/− CNS tissue (Fig. 3F). VSV can drive neuropathological symptoms by infecting the CNS (22). When we measured viral titers in the spinal cord and brain tissue of mice exhibiting hind leg paralysis, we found infectious VSV in tissue from TNFR1-deficient mice (Fig. 3G). Consequently, Tnfrsf1a−/− mice developed clinical signs of CNS infection, unlike WT and Tnfrsf1b−/− mice (Fig. 3H). Taken together, these findings suggest that TNFR1 drives antiviral defense by promoting CD169+ cell survival.

TNFR1 triggers the survival of CD169+ cells. Next, we opted to determine which factors drive the maintenance of CD169+ cells and enforced viral replication after viral infection. B-cell-mediated Ltβ production is important for splenic CD169+ cells. Hence, we wondered whether the defects in the absence of TNF were triggered by B cells.

FIG 1 Legend (Continued)

expression of CD11b, CD11c, Ly6C, Ly6G, F4/80, MHC-II, and CD115 on TNF+ cells (n = 6). The numbers in the boxes are percentages of the population positive for TNF expression. (F) CD3−CD19−NK1.1−CD11b+ Ly6C+ Ly6G− TNF+ cells were quantified in spleen tissue 4 h after infection (n = 6). (G) Mice were injected with liposomes containing phosphate-buffered saline (PBS, PBS liposomes) or clodronate liposomes, and spleen tissue was harvested after 24 h. Sections of snap-frozen spleen tissue were stained with anti-F4/80 antibodies (n = 3). (H) TNF−mRNA expression was determined in the spleens of WT, clodronate-treated WT, Ifnar−/−, DT-treated CD169-DTR, and CD11c-DTR mice 4 h after infection (n = 6). ns, not significant. The error bars indicate SEM.
FIG 2 Tumor necrosis factor is required for early innate immune activation via maintenance of CD169⁺ cells during viral infection. (A to D) Mice were infected with 10⁵ PFU VSV. (A) Survival of WT and TNF-α-null (Tnfa⁻⁻) mice was monitored for 20 days after infection (n = 9 to 12). (B) Titers of neutralizing total immunoglobulin (Ig) (left) and IgG (right) were determined in WT and Tnfa⁻⁻ mice at the indicated time points after infection (n = 7). (C) IFN-α and IFN-β concentrations were determined in the sera of WT and Tnfa⁻⁻ mice 24 h after infection (n = 6 to 9). (D) IFN-α levels were determined in sera from WT and CD169-DTR mice 24 h after infection (n = 6). (E) IFN-α and IFN-β concentrations were determined in the sera of WT and Tnfa⁻⁻ mice injected with 200 µg of poly(I·C) at the indicated time points (n = 3). (F) WT and Tnfa⁻⁻ mice were infected with 2 × 10⁸ PFU of VSV. Snap-frozen spleen sections were stained with anti-CD169 antibodies (clone MOMA-1) at the indicated time points (one representative result out of 6 mice is shown; scale bar = 100 µm). (G) The mean fluorescence intensity (MFI) of CD169 was quantified across spleen sections from naive and VSV-infected WT and Tnfa⁻⁻ mice using ImageJ (1 to 3 images (Continued on next page)
Notably, we did not observe any major changes of B-cell subsets in TNF-, TNFR1-, or TNFR2-deficient mice (Fig. 4A). Consistently, we did not see differential expression of Lta, Ltb, or Ltb receptor (LtbR) in TNFR1-deficient mice (Fig. 4B). Additionally, we found no major differences in B-cell subsets between WT and Tnfrsf1a−/− mice after infection (Fig. 4C). Furthermore, we reconstituted lethally irradiated C57BL/6 mice with mixed bone marrow (BM) from Rag1−/− and Tnfrsf1a−/− and from Rag1−/− and WT donors at a ratio of 1:1. Mice reconstituted with Rag1−/−Tnfrsf1a−/− bone marrow exhibited no significant reduction in IFN-α in the serum compared to mice reconstituted with Rag1−/−WT bone marrow (Fig. 4D). Furthermore, there was no difference between these mice in neutralizing antibody production (Fig. 4E). To elucidate if TNFR1 deficiency specifically on CD169+ cells has a role in virus replication, we reconstituted lethally irradiated C57BL/6 mice with mixed bone marrow from CD169-DTR+ and Tnfrsf1a−/− donors, as well as CD169-DTR+ and WT donors, at a ratio of 1:1. We observed that the production of IFN-α was lower in the mice reconstituted with CD169-DTR+ and Tnfrsf1a−/− bone marrow compared to control mice reconstituted with CD169-DTR+ and WT bone marrow after infection with VSV and DT treatment (Fig. 4F). Furthermore, we found slightly delayed presence of VSV neutralizing antibody titers in CD169-DTR+Tnfrsf1a−/− recipients compared to corresponding CD169-DTR+WT recipients (Fig. 4G). CD169+ cells can be depleted in CD11c-DTR mice, because CD169+ cells exhibit intermediate expression of CD11c (10, 45). Consistently, lethally irradiated mice reconstituted with mixed bone marrow from CD11c-DTR+ and Tnfrsf1a−/− mice exhibited reduced concentrations of IFN-α after VSV infection compared to CD11c-DTR−WT bone marrow recipients (Fig. 4H). These findings suggest that TNFR1 triggers cell-intrinsic effects on CD169+ cells.

We speculated that TNF delivers an important survival signal for CD169+ cells. To determine if TNF is involved in protection against VSV-induced apoptosis, we measured caspase 3 activity on whole spleen tissue lysates. After VSV infection, caspase 3 activity was significantly higher in Tnfa−/− mice than in control animals (Fig. 5A). VSV is known to induce apoptosis and inactivates Mcl-1 and Bcl-XL (46). To elucidate if TNF plays a role in promoting expression of antiapoptotic genes, we measured mRNA expression of Bcl2, Bcl-XL, and xIAP in spleen tissue of mice after VSV infection (Fig. 5B). After VSV infection, Bcl2 and Bcl-XL expression was significantly reduced in Tnfa−/− mice compared to WT mice (Fig. 5B). To enumerate the mechanism that reduces CD169+ cells in TNF-deficient mice after infection, we made use of terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling (TUNEL) assays. The number, as well as the mean fluorescence intensity, of TUNEL-positive CD169+ cells was higher in spleen tissue from TNF-deficient mice than in tissue from corresponding WT control mice (Fig. 5C and D). The proportion of CD169+ cells that stained positive for 7-aminoactinomycin D (7-AAD) was higher in TNFR1-deficient mice than in WT control mice 8 h after infection (Fig. 5E). Next, we wondered if we could rescue the CD169+ cells by injecting the pancaspase inhibitor Z-Val-Ala-Asp-fluoromethylketone (Z-VAD). Z-VAD treatment restored the presence of CD169+ cells in TNF-deficient animals, a finding indicating that CD169+ cells depend on TNF-mediated survival (Fig. 5F and G). Although treatment of TNF-deficient mice with Z-VAD-rescued CD169+ cells, it failed to rescue the IFN-I response, suggesting the role of TNF signaling is essential not only to prevent apoptosis, but also for IFN-I production (Fig. 5H). In summary, these findings indicate that TNF delivers a survival signal that is important for the maintenance of CD169+ cells in the spleen after viral infection and for IFN-I production.

**FIG 2 Legend (Continued)**

per spleen from 3 or 4 mice were analyzed. (H) MFI from Tnfa−/− mice normalized to WT MFI. (I) Snap-frozen spleen sections from WT and Tnfa−/− mice were stained for VSV-G expression (clone Vi10) after infection with 2 × 10⁸ PFU VSV at the indicated time points (one representative result out of 6 mice is shown; scale bar = 100 μm). (J) MFI of VSV-G expression quantified across spleen sections from naive and VSV-infected WT and Tnfa−/− mice using ImageJ (1 to 3 images per spleen from 3 or 4 mice were analyzed). (K) WT and Tnfa−/− mice were infected with 10⁸ PFU VSV. Viral titers were measured in the spleens of WT and Tnfa−/− mice 8 h after infection with VSV (n = 6). (L) Tnfa mRNA expression determined in spleen tissue of WT mice before and 4 h after infection with UV-inactivated VSV (n = 4). (M) Spleen tissue sections were stained with anti-CD169 antibodies in WT and Tnfa−/− mice 8 h after infection with 2 × 10⁸ PFU of UV-inactivated VSV (one representative result out of 3 is shown). (N) Sections from snap-frozen spleen tissue harvested from WT and CD169−/− mice were stained for CD169 and VSV-G 7 h after infection with 2 × 10⁸ PFU VSV (n = 3; scale bar = 100 μm). The error bars indicate SEM.
**FIG 3** VSV replication is sustained via TNFR1 on CD169+ cells. (A) Spleen tissue sections from WT, *Tnfrsf1a−/−* (TNFR1), and *Tnfrsf1b−/−* (TNFR2) mice were stained with anti-CD169 and VSV-G antibodies 8 h after infection with 2 × 10^8 PFU of VSV (one representative result out of 6 mice is shown; scale bar = 100 μm). (B) MFI of CD169 was quantified across spleen sections from WT, *Tnfrsf1a−/−*, and *Tnfrsf1b−/−* infected mice, using ImageJ (1 to 3 images per spleen from 3 or 4 mice were analyzed). (C to G) WT, *Tnfrsf1a−/−*, and *Tnfrsf1b−/−* mice were infected with 10^5 PFU (Continued on next page)
The NF-κB regulator MALT1 promotes canonical NF-κB expression, VSV replication in CD169+ cells, and immune activation during viral infection. TNF can induce NF-κB activation via TNFR1 and can promote the expression of genes driving survival and of proinflammatory cytokines (47). Furthermore, TNF is known to promote IFN-I production (48). Consistently, RelA expression was increased in the marginal zone of spleen tissue after VSV infection (Fig. 6A). We quantified cytoplasmic and nuclear expression of RelA in CD169+ cells. The nuclear presence of RelA in CD169+ cells was higher in VSV-infected mice than in naive controls (Fig. 6B). We wondered whether nuclear RelA protein expression was dependent on TNF. As expected, compared with WT control mice, VSV-infected mice exhibited reduced expression of RelA in the nuclear compartments of CD169+ cells in the absence of TNF (Fig. 6C). Notably, the presence of RelA was reduced in TNFR1-deficient mice, but we observed no difference in RelA expression between TNFR2-deficient mice and corresponding control mice (Fig. 6D and E). It has been reported that one of the major regulators of RelA signaling is RelB, which acts through sequestration of RelA in the cytoplasm and competitive binding of DNA (49). It has also been reported that the paracaspase MALT1 can promote canonical NF-κB signaling by cleaving RelB (50, 51). Hence, we stained spleen sections of Malt1−/− and Malt1−/−−/− mice for RelB. Ablation of MALT1 resulted in increased levels of RelB in CD169+ cells in the marginal zone of the spleen (Fig. 7A and B). In turn, nuclear RelA levels were lower in CD169+ cells in Malt1−/−−/− spleen tissue than in control tissue (Fig. 7C). Consistently, mouse embryonic fibroblasts (MEFs) derived from Malt1−/−−/− mice showed reduced translocation of p65 into the nucleus after stimulation with TNF but higher expression of RelB in the nucleus (Fig. 7D and E). These findings indicate that MALT1 destabilizes RelB in marginal-zone macrophages to promote canonical NF-κB signaling. The presence of CD169+ cells in spleen tissue was not affected by Malt1 before or after infection with VSV (Fig. 8A). However, the expression of VSV-G was lower in Malt1−/−−/− mice than in control mice (Fig. 8B and C). Consistently, the numbers of infectious VSV particles were lower in spleen tissue harvested from Malt1−/−−/− mice than in spleen tissue from control mice (Fig. 8D). Hence, serum IFN-I concentrations after VSV infection were lower in MALT1-deficient mice than in control mice (Fig. 8E). A previous report suggested that MALT1 is not required for RIG-I activation (52). Consistently, when we injected poly(I·C) into Malt1−/−−/− and Malt1−/−−/−−/− mice, we found similar serum IFN-I levels in both groups (Fig. 8F). Hence, we concluded that defective IFN-I production during VSV infection was caused by reduced VSV replication early during infection. Consequently, MALT1-deficient mice succumbed to the infection, in sharp contrast to control animals (Fig. 8G).

Taken together, these findings indicate that absence of MALT1 results in reduced canonical NF-κB signaling in response to VSV infection. Malt1−/− mice exhibit reduced VSV replication and immune activation.

**DISCUSSION**

In this study, we found that TNF plays a crucial role in the maintenance of CD169+ cells early after infection with VSV. Consequently, TNF−/−, TNFR1−/−, and MALT1-deficient animals exhibited reduced immune activation and limited IFN-I production, which consequently led to severe VSV infection.

The role of TNF during viral infection is controversial and not sufficiently under-
FIG 4 TNFR1 on CD169+ cells is essential for early IFN-I response. (A) Follicular B cells (CD19+ CD23+) (FB), marginal-zone B cells (CD19+ CD21+ CD23+) (MZB), and regulatory B cells (CD19+ CD21+ CD5+ IgM+) (RB) were analyzed in naive WT and Tnfa−/−, Tnfrsf1a−/−, and Tnfrsf1b−/−-deficient mice (n=6). (B) Lymphotoxin α (Ltα), Ltβ, and lymphotoxin β receptor (LtBR) gene expression was determined in spleen tissue from WT and Tnfrsf1a−/− mice by RT-PCR (n=3). (C) Splenic B-cell populations (FB, MZB, and RB) were analyzed after infection with 2×10⁶ PFU of VSV in WT and Tnfrsf1a−/− mice at the indicated time points (n=3). (D) IFN-α concentrations were determined 24 h after infection with 10⁵ PFU VSV in the sera of lethally irradiated mice reconstituted with either WT-Rag−/− or Tnfrsf1a−/−-Rag−/− bone marrow at a ratio of 1:1 (n=4). (E) Neutralizing total immunoglobulin (left) and IgG (right) antibody titers were determined in the sera of WT–CD169-DTR and Tnfrsf1a−/−–CD169-DTR reconstituted animals (n=4 or 5). (F) IFN-α concentrations were determined 24 h after infection in the sera of WT–CD11c-DTR and Tnfrsf1a−/−–CD11c-DTR reconstituted mice (n=4 or 5). The error bars indicate SEM.
FIG 5 Tumor necrosis factor mediates survival of CD169+ cells via TNFR1. (A to E) Mice were infected with 2 × 10^8 PFU VSV. (A) Caspase 3 activity was determined in spleen tissue harvested from WT and Tnfa−/− mice 6 h after infection with 2 × 10^8 PFU VSV (n = 4 to 7). (B) Bcl2, Bclxl, and Xiap RNA expression was determined in spleen tissue from WT and Tnfrsf1a−/− mice 8 h after infection (n = 3). (C) Tissue sections from WT and Tnfa−/− mice were TUNEL stained 5 h after infection (one result representative of 3 or 4 mice is shown; scale bar = 10 μm). (D) MFI of TUNEL quantified across spleen sections from naive and VSV-infected WT and Tnfa−/− mice using ImageJ (1 or 2 images per spleen from 3 or 4 mice were analyzed). (E) At the indicated time points, the proportions of 7AAD+ cells among CD11b+ CD169+ cells were determined (n = 3) in WT and Tnfrsf1a−/− mice. (F) WT, Tnfa−/−, and Tnfrsf1a−/− mice were treated with Z-VAD and infected with 2 × 10^8 PFU VSV. Spleen tissue sections were stained with anti-CD169 antibodies 8 h after infection (one result representative of 3 or 4 mice is shown; scale bar = 100 μm). (G) MFI of CD169 quantified across spleen sections from naive and VSV-infected WT and Tnfa−/− mice treated with Z-VAD, using ImageJ (1 to 3 images per spleen from 3 or 4 mice were analyzed). (H) IFN-α concentrations determined 24 h after infection in the sera of Z-VAD-treated WT and Tnfa−/− mice after infection with 10^5 PFU of VSV (n = 3). The error bars indicate SEM.
stood. Although reports describe activating polymorphisms in TNF, which are associated with the establishment of a chronic viral infection (53), other reports state that the same mutations are protective against chronic hepatitis B virus (HBV) infection (54). In vitro, TNF can propagate the replication of hepatitis C virus (HCV) (55), although HCV increases the incidence of TNF-induced apoptosis (56). On the other hand, TNF strongly inhibits influenza virus replication in porcine lung epithelial cells (57). Consistently, the attenuation of TNF signaling in a murine T-cell-independent model of HBV infection...
results in viral persistence (58). In turn, the application of second mitochondrion-derived activator of caspases (SMAC) mimetics enhances TNF signaling and is associated with increased clearance of HBV in this model system (59). During infection with VSV, the production of neutralizing antibodies is not defective in the absence of TNFR1 (32). Moreover, TNF can induce T-cell dysfunction and therefore promote chronic viral

FIG 7 MALT1 regulates nuclear RelA expression after infection with vesicular stomatitis virus. (A) Sections from snap-frozen spleen tissue harvested from naive Malt1+/− and Malt1−/− mice were stained with anti-RelB antibodies (one representative result out of 3 is shown; scale bar = 10 μm). (B) MFI of cytoplasmic and nuclear RelB was quantified in CD169+ cells using ImageJ (n = 39 to 42). (C) Sections of snap-frozen spleen tissue from Malt1+/− and Malt1−/− mice were stained with anti-RelA antibodies 4 h after infection with 2 × 106 PFU VSV. The MFI in the nuclei of CD169+ cells was quantified (n = 29 to 41). (D and E) Malt1+/− and Malt1−/− MEFs were stimulated with 100 ng/ml recombinant mouse tumor necrosis factor (rmTNF) at the indicated time points. Cytosolic extracts (CE) and nuclear extracts (NE) were harvested and probed for p65. Densitometry analysis of p65 and RelB was performed on the Western blot (WB) images from cytosolic and nuclear fractions at the indicated time points. Proteins were normalized to GAPDH or histone (n = 4). The error bars indicate SEM.
infection (60). Our finding that TNF is crucial for the maintenance of CD169+ cells in spleen tissue may be important for infections with lower doses of virus, because allowing viral replication in CD169+ cells is particularly important for protective adaptive immunity (9, 13). This may be crucial for the maintenance of CD169+ cells in spleen tissue during vaccination with attenuated virus strains or VSV vector-based vaccines (25). These findings may not be specific only for splenic CD169+ cells, since intranasal infection with recombinant TNF overexpressing rabies virus (RV) reduced the RV load and mortality (61).

Viral replication in CD169+ cells, which is promoted by TNF, contributes to improved antigen presentation. CD169+ cells in the marginal zone are in close contact with
pathogens and are ideally situated to induce an immune response (62). Furthermore, CD169+ cells have been shown not only to present antigens to B cells in the lymph nodes, but also to prime T cells (11, 63). Moreover, CD169+ cells are important for virus-mediated IFN-I production, which prevents severe CNS infection in mice (64). Our findings show that TNF promotes maintenance of CD169+ cells and IFN-I production following VSV infection. Furthermore, our findings show that the translocation of RelA to the nuclei of CD169+ cells after VSV infection is dependent on TNF. It has been postulated that canonical NF-κB can contribute to the production of IFN-α (65, 66). However, RelA-deficient and p50-deficient MEFs can produce IFN-α after viral infection, whereas only early IFN-I transcription is reduced (67, 68). Furthermore, RelA-deficient plasmacytoid dendritic cells (pDCs) exhibited reduced IFN production after exposure to Sendai virus (69). Our findings indicate that canonical NF-κB activation can also promote early viral replication and consequently contribute to the production of IFN-I. Consistently, noncanonical NF-κB, which can inhibit canonical NF-κB signaling, is a potent inhibitor of IFN-I production (70). Hence, the paracaspase MALT1, which can cleave RelB and consequently promote canonical NF-κB signaling (50, 51), is necessary for the sufficient propagation of VSV replication and IFN-I production.

Taken together, we have found that TNF-TNFRI signaling is crucial for protecting CD169+ cells and their function in innate immune activation during VSV infection.

MATERIALS AND METHODS

Mice, viruses, and virus titration. Tnfa−/−, Tnfrsf1b−/−, CD8−/−, and Rag1−/− mice were purchased from Jackson Laboratories (United States). Tnfrsf1a−/− mice have been previously described (34). Malt1−/−, CD169−/−, CD169-DTR, and CD11c-DTR mice have also been previously described (71–74). All the mice were maintained on a C57BL/6 genetic background. VSV Indiana serotype (Mudd-Summers strain) was originally obtained from D. Kolakofsky (University of Geneva, Geneva, Switzerland). VSV was propagated and titrated as previously described (13). Mice were infected with VSV via tail vein injection. In survival experiments, mice exhibiting symptoms of hind leg paralysis were considered “severe,” taken out of the experiment, and counted as dead. Blood was collected at the indicated time points after infection. VSV neutralizing antibody titers were measured by plaque reduction neutralization test (PRNT) as previously described (9, 13). Briefly, serum samples were diluted 1:40 and incubated at 56°C for 30 min. To evaluate immunoglobulin G (IgG), the serum was pretreated with 0.1 M β-mercaptoethanol. Serial 2-fold dilutions were performed for 12 steps, and the serum was incubated with 5,000 PFU of VSV. The virus and serum mixture was incubated on a Vero cell monolayer. The plates were stained with crystal violet after 24 h. To inhibit caspase activity in vivo, we administrated three doses (2 μg/g of body weight each) of Z-VAD (Abcam, Cambridge, United Kingdom) (75, 76). For chimera experiments, mice were lethally irradiated with 10.2 Gy. After 24 h, mixed bone marrow from WT or Tnfrsf1a−/− and CD169-DTR, CD11c-DTR, and Rag1−/− mice was transplanted into the irradiated mice as indicated. All mice were maintained under specific-pathogen-free conditions under the authorization of the Landesamt für Natur, Umwelt und Verbraucherschutz of North Rhine-Westphalia (LANUV NRW) in accordance with the German laws for animal protection.

Depletion of cells. To deplete macrophages, 200 μl clodronate liposomes was injected intravenously, and 24 h later, the mice were infected with VSV. Liposomes containing phosphate-buffered saline (PBS; PBS liposomes) were used as a control. Clodronate and PBS liposomes were provided by Nico van Rooijen (Vrije University Medical Center, Netherlands) and used as previously described (41, 42). CD169- and CD11c-expressing cells in CD169-DTR and CD11c-DTR mice were depleted by injecting 2 doses of 100 ng DT (Sigma) 1 day before and on the day of infection.

Histology and ELISA. Histological analysis of snap-frozen tissue was performed as previously described (9). Briefly, snap-frozen tissue sections were cut at 7-μm thickness, air dried, and fixed with acetone for 10 min. The sections were blocked with 2% fetal calf serum in phosphate-buffered saline (PBS) for 1 h and stained with anti-CD169 (final concentration, 1 μg/ml; Acris, Germany; clone MOMA-1), anti-VSV-G (final concentration, 1 μg/ml; produced in house; clone V110), anti-RelA (final concentration, 1 μg/ml; Santa Cruz Biotechnology, USA), anti-F4/80 (final concentration, 2 μg/ml; eBioscience; clone BMB), and anti-RelB (final concentration, 1 μg/ml; Cell Signaling, USA; polyclonal) for 1 h. Then, the sections were washed with PBS containing 0.05% Tween 20 (Sigma). The secondary antibodies, phycoerythrin (PE) streptavidin (final concentration, 1 μg/ml; eBioscience), anti-rabbit fluorescein isothiocyanate (FITC) (final concentration, 1 μg/ml; Thermo Fisher), and anti-goat FITC (final concentration, 1 μg/ml; Santa Cruz Biotechnology, USA), were incubated for 1 h. Then, the sections were washed with PBS containing 0.05% Tween 20 (Sigma) and mounted using fluorescence mounting medium (Dako). A caspase 3 activity assay was performed with a fluorescence assay (Cell Signaling) according to the manufacturer’s instructions. TUNEL staining was performed on formalin-fixed spleen sections according to the manufacturer’s instructions (Thermo Scientific, USA). Images were obtained with an LSM510 confocal microscope and an Axio Observer Z1 fluorescence microscope (Zeiss, Germany). Analysis of the fluorescence images was performed with ImageJ software. IFN-α and IFN-β (PBL Biosciences, New Jersey, February 2018 Volume 92 Issue 3 e01637-17 jvi.asm.org 15
USA) concentrations were determined using an enzyme-linked immunosorbent assay (ELISA) according to the manufacturers’ instructions.

Reverse transcription (RT)-PCR analyses. RNA purification (Qiagen RNeasy kit or TRIzol) was performed according to the manufacturer’s instructions. Gene expression of B22, Bcl-xL, Xiap, Lta, Ltb, Ifi17, Ifi27, Ifi30, Ifi35, Isg15, Nos2, and Tnfa was performed using 6-carboxyfluorescein (FAM) and VIC probes (Applied Biosystems) and an iTAQ one-step PCR kit (Bio-Rad). For analysis, the expression levels of all the target genes were normalized to β-actin/GAPDH (glyceraldehyde-3-phosphate dehydrogenase) expression (ΔΔCt). Gene expression values were then calculated based on the ΔΔCt method, using naive WT mice as a control to which all other samples were compared. Relative quantities (RQ) were determined using the following equation: RQ = 2−ΔΔCt.

Immunoblotting. Malt1−/− and Malt1+/− MEFs were obtained from Jürgen Ruland (Technische Universität München, Munich, Germany). Malt1−/− and Malt1+/− MEFs were stimulated with 100 ng/ml murine soluble TNF (sTNF) (BD Biosciences, USA). Cytoplasmic and nuclear extracts were prepared using a nuclear protein extraction kit according to the manufacturer’s instructions (Active Motif, Belgium). Immunoblots were probed with primary anti-p65 (Santa Cruz Biotechnology), anti-RelB (Cell Signaling), and anti-p100/p52 (Cell Signaling). Immunoblots were probed with primary anti-TNF antibodies (eBioscience) for 30 min incubated with brefeldin A (eBioscience), followed by an additional 5 hour incubation at 37°C. After surface staining with anti-CD21, anti-CD23, and anti-IgM antibodies (all from eBioscience), BD Calibrite (BD Biosciences, USA) formalin, permeabilized with 0.1% saponin, and stained with anti-TNF antibodies (eBioscience) for 30 min at 4°C. B-cell subsets were detected in single-cell suspensions of splenocytes with anti-CD3, anti-CD19, anti-CD21, anti-CD11b, anti-CD11c, anti-CD19, anti-CD15, anti-Ly-6G, anti-MHC-II, and anti-NK1.1 antibodies (all from eBioscience), the cells were fixed with 2% formalin, permeabilized with 0.1% saponin, and stained with anti-TNF antibodies (eBioscience) for 30 min at 4°C. B-cell subsets were detected in single-cell suspensions of splenocytes with anti-CD3, anti-CD19, anti-CD21, anti-CD23, and anti-IgM antibodies (all from eBioscience).

Flow cytometry. For intracellular-cytokine staining, single-cell suspended splenocytes were incubated with brefeldin A (eBioscience), followed by an additional 5 h of incubation at 37°C. After surface staining with anti-CD3, anti-CD8, anti-CD11b, anti-CD11c, anti-CD19, anti-CD15, anti-Ly-6G, anti-MHC-II, and anti-NK1.1 antibodies (all from eBioscience), the cells were fixed with 2% formalin, permeabilized with 0.1% saponin, and stained with anti-TNF antibodies (eBioscience) for 30 min at 4°C. B-cell subsets were detected in single-cell suspensions of splenocytes with anti-CD3, anti-CD19, anti-CD21, anti-CD23, and anti-IgM antibodies (all from eBioscience).

Statistical analyses. Data are represented with standard errors of the mean (SEM). Statistically significant differences between two groups were determined with Student’s t test. Statistically significant differences between several groups were determined by one-way analysis of variance (ANOVA) with additional Bonferroni or Dunn post hoc tests. Statistically significant differences between groups in experiments involving more than one time point were determined with two-way ANOVA (repeated measurements).

ACKNOWLEDGMENTS

We thank Flo Witte for valuable comments on the manuscript. This study was supported by the Alexander von Humboldt Foundation (SKA2010), the German Research Council (SF87974, LA2558/3-1, LA2558/5-1, GRK1949, and TRR60), Jürgen Manchot Graduate School MOI II, and the NIH tetramer facility. D.B. is funded by the ATTRACTION Programme (A14/BM/7632103/DBBRIL) and a CORE grant (C15/BM/10355103) from the National Research Fund Luxembourg (FNR). J.R. is funded by the Alexander von Humboldt (SKA2010), the German Research Council (SFB974, LA2558/3-1, LA2558/5-1, GRK1949, and TRR60), Jürgen Manchot Graduate School MOI II, and the NIH tetramer facility. D.B. is funded by the ATTRACTION Programme (A14/BM/7632103/DBBRIL) and a CORE grant (C15/BM/10355103) from the National Research Fund Luxembourg (FNR). J.R. is funded by the Alexander von Humboldt (SKA2010), the German Research Council (SFB974, LA2558/3-1, LA2558/5-1, GRK1949, and TRR60), Jürgen Manchot Graduate School MOI II, and the NIH tetramer facility. D.B. is funded by the ATTRACTION Programme (A14/BM/7632103/DBBRIL) and a CORE grant (C15/BM/10355103) from the National Research Fund Luxembourg (FNR).

REFERENCES


February 2018 Volume 92 Issue 3 e01637-17 jvi.asm.org

Shinde et al. Journal of Virology